ArticleZhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics2026
[Efficacy and safety of rituximab in children with refractory nephrotic syndrome].
Article in Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the efficacy and safety of rituximab (RTX) in children with frequently relapsing nephrotic syndrome (FRNS) or steroid-dependent nephrotic syndrome (SDNS) after treatment with prednisone combined with standard doses of mycophenolate mofetil and a calcineurin inhibitor.
methodsA retrospective analysis was conducted on clinical data from pediatric patients admitted to the Department of Pediatric Nephrology, Peking University First Hospital from January 1, 2014 to December 31, 2023. These patients had received prednisone plus standard doses of mycophenolate mofetil and a calcineurin inhibitor but still presented with FRNS or SDNS. Outcomes included remission rate, relapse rate, reduction or discontinuation of steroids and oral immunosuppressants after RTX treatment, and adverse events following RTX.
resultsEighteen patients were enrolled, receiving 63 courses of RTX treatment. None presented with FRNS or SDNS after RTX treatment. Among them, 11 patients experienced no relapse from the first RTX dose to the last follow-up. After RTX administration, the duration of use of all immunosuppressants and the relapse frequency were significantly reduced (
conclusionsRTX demonstrates good efficacy and safety in children with FRNS or SDNS after treatment with three immunosuppressive agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.